<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ORAVERSE- phentolamine mesylate injection, solution </strong><br>Novalar Pharmaceuticals<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">OraVerse is indicated for the reversal of soft-tissue anesthesia, i.e., anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor. OraVerse is not recommended for use in children less than 6 years of age or weighing less than 15 kg (33 lbs). ( <a href="#INV-7663ea41-5582-459d-8380-719dfd3129ba">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<a name="INV-e1f58ef6-d9d6-41f4-9f92-656775227f71"></a><table frame="void">
<col align="left">
<col align="left">
<tbody class="Headless" valign="top">
<tr class="First" valign="top">
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<span class="Bold">Amount of Local</span><br><span class="Bold">Anesthetic Administered</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">
<span class="Bold">Dose of</span><br><span class="Bold">OraVerse</span>
</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule" align="center" valign="middle">½ Cartridge</td>
<td class="Botrule Rrule" align="center" valign="middle">½ Cartridge (0.2 mg)</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule" align="center" valign="middle">1 Cartridge</td>
<td class="Botrule Rrule" align="center" valign="middle">1 Cartridge (0.4 mg)</td>
</tr>
<tr class="Last" valign="top">
<td class="Lrule Rrule" align="center" valign="middle">2 Cartridges</td>
<td class="Rrule" align="center" valign="middle">2 Cartridges (0.8 mg)</td>
</tr>
</tbody>
</table>
<p class="Highlighta">OraVerse is administered using the same location(s) and same technique(s) (infiltration or block injection) used for the administration of local anesthetic. ( <a href="#INV-ef874211-5a67-441e-b790-0085bb5ec83b">2.1</a>) </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">0.4 mg/1.7 mL solution per cartridge ( <a href="#INV-6775d562-ec0c-4919-a170-b5ff5129ddfe">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None ( <a href="#INV-81de7104-500e-49e8-a42d-bd6eb854e207">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4249605" conceptname="Spasm of cerebral arteries">cerebrovascular spasm</span>, and cerebrovascular occlusion have been reported to occur following the intravenous or intramuscular administration of phentolamine, usually in association with marked <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotensive episodes</span> or <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>-like states which occasionally follow parenteral administration. </p>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span> and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> may occur with the use of phentolamine or other alpha-adrenergic blocking agents. ( <a href="#INV-2e32c8b7-fbb6-4e91-a8d9-bf63a99c6905">5.1</a>) </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta">The most common adverse reaction with OraVerse (incidence ≥ 5% and &gt; control) is injection-site <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. ( <a href="#INV-ca0c3e0e-0b51-44c5-b3c8-eaa6d57db7df">6</a>) </p></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>Use in pediatric patients less than 6 years of age or &lt;15 kg (33 lbs) is not recommended. (<a href="#INV-f30b7487-3927-49d0-abfb-45aa2dd5be9f">8.4</a>)</li>
<li>In pediatric patients weighing less than 30 kg (66 lbs), the maximum dose of OraVerse recommended is 1/2 cartridge (0.2 mg). (<a href="#INV-f30b7487-3927-49d0-abfb-45aa2dd5be9f">8.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 5/2008</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-2" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-3" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-3.1" class="toc">2.1 General Dosing Information</a></h2>
<h2><a href="#section-3.2" class="toc">2.2 Dosing in Special Populations</a></h2>
<h1><a href="#section-4" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-5" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-6" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">5.1 Cardiovascular Events</a></h2>
<h1><a href="#section-7" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-7.2" class="toc">6.2 Adverse Reactions in Clinical Trials</a></h2>
<h2><a href="#section-7.3" class="toc">6.3 Post Marketing Adverse Reaction Reports from Literature and Other Sources</a></h2>
<h1><a href="#section-8" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-8.1" class="toc">7.1 Lidocaine and Epinephrine</a></h2>
<h1><a href="#section-9" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-9.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-9.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-9.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-9.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section">
<a name="section-1"></a><p></p>
<h1></h1>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="INV-7663ea41-5582-459d-8380-719dfd3129ba"></a><a name="section-2"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First"><a name="INV-53d632aa-d6d3-47be-936f-f300b752ed17"></a>OraVerse is indicated for reversal of the soft-tissue anesthesia, i.e., anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor. OraVerse is not recommended for use in children less than 6 years of age or weighing less than 15 kg (33 lbs).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="INV-a16c0d08-35ab-46eb-896c-d9280ef6522d"></a><a name="section-3"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section">
<a name="INV-ef874211-5a67-441e-b790-0085bb5ec83b"></a><a name="section-3.1"></a><p></p>
<h2>2.1 General Dosing Information</h2>
<p class="First"><a name="INV-8b8c1f2f-b66b-493d-8821-4f264f50141a"></a>The recommended dose of OraVerse is based on the number of cartridges of local anesthetic with vasoconstrictor administered:</p>
<a name="INV-324f8441-7897-4dc2-b74f-15f9baa3b04d"></a><table frame="void">
<col align="left" width="154px">
<col align="left" width="154px">
<col align="left" width="154px">
<tbody class="Headless" valign="top">
<tr class="First" valign="top">
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<span class="Bold">Amount of Local</span><br><span class="Bold">Anesthetic Administered</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">
<span class="Bold">Dose of OraVerse</span><br><span class="Bold">[mg]</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">
<span class="Bold">Dose of OraVerse</span><br><span class="Bold">[Cartridge]</span>
</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule" align="center" valign="middle">½ Cartridge</td>
<td class="Botrule Rrule" align="center" valign="middle">0.2</td>
<td class="Botrule Rrule" align="center" valign="middle">½</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule" align="center" valign="middle">1 Cartridge</td>
<td class="Botrule Rrule" align="center" valign="middle">0.4</td>
<td class="Botrule Rrule" align="center" valign="middle">1</td>
</tr>
<tr class="Last" valign="top">
<td class="Lrule Rrule" align="center" valign="middle">2 Cartridges</td>
<td class="Rrule" align="center" valign="middle">0.8</td>
<td class="Rrule" align="center" valign="middle">2</td>
</tr>
</tbody>
</table>
<p><a name="INV-eefb8b7a-c98d-4a49-ae20-19c57182e27e"></a>OraVerse should be administered following the dental procedure using the same location(s) and technique(s) (infiltration or block injection) employed for the administration of the local anesthetic.</p>
<p><a name="INV-ed82a7d4-ebeb-4f5f-a698-b804eb435cc4"></a>Note: Do not administer OraVerse if the product is discolored or contains particulate matter.</p>
</div>
<div class="Section">
<a name="INV-f12c0ac5-be75-471a-a71a-e0c498d30221"></a><a name="section-3.2"></a><p></p>
<h2>2.2 Dosing in Special Populations</h2>
<p class="First"><a name="INV-bcbfe1dc-9e21-4e42-b637-6edeb82d2be0"></a>In pediatric patients weighing 15-30 kg, the maximum dose of OraVerse recommended is 1/2 cartridge (0.2 mg).</p>
<p><a name="INV-26706a1c-bf6f-4e8e-b970-72563e9cad42"></a>(Note: Use in pediatric patients under 6 years of age or weighing less than 15 kg (33 lbs) is not recommended. A dose of more than 1 cartridge [0.4 mg] of OraVerse has not been studied in children less than 12 years of age.)</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="INV-6775d562-ec0c-4919-a170-b5ff5129ddfe"></a><a name="section-4"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First"><a name="INV-aeae948e-08bd-4867-832f-3a1e3ef766bf"></a>0.4 mg/1.7 mL solution per cartridge</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="INV-81de7104-500e-49e8-a42d-bd6eb854e207"></a><a name="section-5"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First"><a name="INV-6f67a84e-9d2d-4a35-9c79-3e6115e986eb"></a>None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="INV-fca25cf5-8a3f-44e7-8c37-82852b75a16f"></a><a name="section-6"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section">
<a name="INV-2e32c8b7-fbb6-4e91-a8d9-bf63a99c6905"></a><a name="section-6.1"></a><p></p>
<h2>5.1 Cardiovascular Events</h2>
<p class="First"><a name="INV-d6179dfb-d2c4-4183-b8c0-6386a2bcaeda"></a><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4249605" conceptname="Spasm of cerebral arteries">cerebrovascular spasm</span>, and cerebrovascular occlusion have been reported to occur following the parenteral administration of phentolamine.  These events usually occurred in association with marked <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotensive episodes</span> producing <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>-like states.</p>
<p><a name="INV-4f32e76b-8825-4811-83aa-40c58fb69b0e"></a><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span> and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> may occur with the use of phentolamine or other alpha-adrenergic blocking agents. Although such effects are uncommon after administration of OraVerse, clinicians should be alert to the signs and symptoms of these events, particularly in patients with a prior history of cardiovascular disease.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="INV-ca0c3e0e-0b51-44c5-b3c8-eaa6d57db7df"></a><a name="section-7"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First"><a name="INV-29705f0f-67f5-4c3a-a158-f26725b4e00a"></a>In clinical trials, the most common adverse reaction with OraVerse that was greater than the control group was <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">injection site pain</span>.</p>
<div class="Section">
<a name="INV-2444d9c6-e643-447e-9c44-e587c4322bc3"></a><a name="section-7.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First"><a name="INV-b0f1d6bd-9b49-4ca9-bf49-5dbb5eb7ab80"></a>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p><a name="INV-dea3e574-6ddc-4b4e-8f48-a7365d3437a7"></a>Dental patients were administered a dose of either 0.2, 0.4 or 0.8 mg of OraVerse. The majority of adverse reactions were mild and resolved within 48 hours.  There were no serious adverse reactions and no discontinuations due to adverse reactions.</p>
<p><a name="INV-8bf55817-8883-4f11-84c8-d283f941f69f"></a>Table 1 lists adverse reactions where the frequency was greater than or equal to 3% in any OraVerse dose group and was equal to or exceeded that of the control group.</p>
<a name="INV-5b34fc1e-e0ab-4f2a-ac38-ee2c82cacad7"></a><table frame="void">
<caption><span>Table 1: Adverse Reactions with Frequency Greater Than or Equal to 3% and Equal to or Exceeding Control</span></caption>
<col width="150px">
<col width="90px">
<col width="90px">
<col width="90px">
<col width="90px">
<col width="90px">
<thead valign="bottom"><tr class="Last" valign="bottom">
<td class="Botrule" align="center" valign="bottom"></td>
<td class="Botrule" align="center" valign="bottom"></td>
<td class="Botrule" align="center" valign="bottom"></td>
<td class="Botrule" align="center" valign="bottom"></td>
<td class="Botrule" align="center" valign="bottom"></td>
<td class="Botrule" align="center" valign="bottom"></td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule" valign="middle"><span class="Bold">Adverse Event</span></td>
<td class="Botrule" valign="middle">   </td>
<td class="Botrule" align="center" valign="middle"><span class="Bold">OraVerse</span></td>
<td class="Botrule" valign="middle">   </td>
<td class="Botrule" valign="middle">   </td>
<td class="Botrule" align="center" valign="middle"><span class="Bold">Control</span></td>
</tr>
<tr>
<td class="Botrule" valign="middle"> </td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">0.2 mg</span><br><span class="Bold">(N = 83)</span>
</td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">0.4 mg</span><br><span class="Bold">(N = 284)</span>
</td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">0.8 mg</span><br><span class="Bold">(N = 51)</span>
</td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">Total</span><br><span class="Bold">(N = 418)</span>
</td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">Total</span><br><span class="Bold">(N = 359)</span>
</td>
</tr>
<tr>
<td class="Botrule" valign="middle"> </td>
<td class="Botrule" align="center" valign="middle"><span class="Bold">N (%)</span></td>
<td class="Botrule" align="center" valign="middle"><span class="Bold">N (%)</span></td>
<td class="Botrule" align="center" valign="middle"><span class="Bold">N (%)</span></td>
<td class="Botrule" align="center" valign="middle"><span class="Bold">N (%)</span></td>
<td class="Botrule" align="center" valign="middle"><span class="Bold">N (%)</span></td>
</tr>
<tr>
<td class="Botrule" valign="middle">Patients with AEs</td>
<td class="Botrule" align="center" valign="middle">15 (18)</td>
<td class="Botrule" align="center" valign="middle">82 (29)</td>
<td class="Botrule" align="center" valign="middle">20 (39)</td>
<td class="Botrule" align="center" valign="middle">117 (28)</td>
<td class="Botrule" align="center" valign="middle">96 (27)</td>
</tr>
<tr>
<td class="Botrule" valign="middle">   <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></td>
<td class="Botrule" align="center" valign="middle">0 (0)</td>
<td class="Botrule" align="center" valign="middle">17 (6)</td>
<td class="Botrule" align="center" valign="middle">2 (4)</td>
<td class="Botrule" align="center" valign="middle">19 (5)</td>
<td class="Botrule" align="center" valign="middle">20 (6)</td>
</tr>
<tr>
<td class="Botrule" valign="middle">   <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span></td>
<td class="Botrule" align="center" valign="middle">0 (0)</td>
<td class="Botrule" align="center" valign="middle">5 (2)</td>
<td class="Botrule" align="center" valign="middle">2 (4)</td>
<td class="Botrule" align="center" valign="middle">7 (2)</td>
<td class="Botrule" align="center" valign="middle">1 (0.3)</td>
</tr>
<tr>
<td class="Botrule" valign="middle">   <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">Injection site pain</span></td>
<td class="Botrule" align="center" valign="middle">5 (6)</td>
<td class="Botrule" align="center" valign="middle">15 (5)</td>
<td class="Botrule" align="center" valign="middle">2 (4)</td>
<td class="Botrule" align="center" valign="middle">22 (5)</td>
<td class="Botrule" align="center" valign="middle">14 (4)</td>
</tr>
<tr>
<td class="Botrule" valign="middle">   <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">Post procedural pain</span></td>
<td class="Botrule" align="center" valign="middle">3 (4)</td>
<td class="Botrule" align="center" valign="middle">17 (6)</td>
<td class="Botrule" align="center" valign="middle">5 (10)</td>
<td class="Botrule" align="center" valign="middle">25 (6)</td>
<td class="Botrule" align="center" valign="middle">23 (6)</td>
</tr>
<tr class="Last">
<td class="Botrule" valign="middle">   <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule" align="center" valign="middle">0 (0)</td>
<td class="Botrule" align="center" valign="middle">10 (4)</td>
<td class="Botrule" align="center" valign="middle">3 (6)</td>
<td class="Botrule" align="center" valign="middle">13 (3)</td>
<td class="Botrule" align="center" valign="middle">14 (4)</td>
</tr>
</tbody>
</table>
<p><a name="INV-28af5d34-e2a5-4d8a-93fd-5345bfec5506"></a>An examination of population subgroups did not reveal a differential adverse reaction incidence on the basis of age, gender, or race.</p>
<p><a name="INV-9451230c-6c5d-4370-b9b6-fb5cd0d06e6e"></a>Results from the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> assessments in Study 1 and Study 2, involving mandibular and maxillary procedures, respectively, indicated that the majority of dental patients in both OraVerse and control groups experienced no or mild <span class="product-label-link" type="condition" conceptid="4010025" conceptname="Painful mouth">oral pain</span>, with less than 10% of patients in each group reporting moderate <span class="product-label-link" type="condition" conceptid="4010025" conceptname="Painful mouth">oral pain</span> with a similar distribution between the OraVerse and control groups.  No patient experienced severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in these studies.</p>
</div>
<div class="Section">
<a name="INV-a13a10bd-2cc1-4326-9087-7cacebb2e3f3"></a><a name="section-7.2"></a><p></p>
<h2>6.2 Adverse Reactions in Clinical Trials</h2>
<p class="First"><a name="INV-f8313884-72f1-4909-aa73-f009d03e5b1c"></a>Adverse reactions reported by less than 3% but at least 2 dental patients receiving OraVerse and occurring at a greater incidence than those receiving control, included <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">facial swelling</span>, <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span>/<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span>, <span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">jaw pain</span>, <span class="product-label-link" type="condition" conceptid="4010025" conceptname="Painful mouth">oral pain</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">upper abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. The majority of these adverse reactions were mild and resolved within 48 hours. The few reports of <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> were mild and transient and resolved during the same time period.</p>
</div>
<div class="Section">
<a name="INV-d16ea495-2536-406c-ab3c-1b5b0330af98"></a><a name="section-7.3"></a><p></p>
<h2>6.3 Post Marketing Adverse Reaction Reports from Literature and Other Sources</h2>
<p class="First"><a name="INV-1d7600b2-8bd7-48cc-a554-2877627a3fb4"></a>The following adverse reactions have been identified during postapproval parenteral use of phentolamine mesylate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><a name="INV-1e6b6e77-4005-4b00-9475-4cf3b6e60bac"></a>Acute and prolonged <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotensive episodes</span> and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> have been reported with the use of phentolamine. In addition, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, and <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal stuffiness</span> have occurred.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="INV-346633be-c7f2-44f4-aa34-211a688b0b70"></a><a name="section-8"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First"><a name="INV-cdd661ec-7e22-4dcd-8ed0-879fdd5f0c90"></a>There are no known drug interactions with OraVerse.</p>
<div class="Section">
<a name="INV-c33702a4-0aa9-4e0c-a3fb-1ec318e9cdb7"></a><a name="section-8.1"></a><p></p>
<h2>7.1 Lidocaine and Epinephrine</h2>
<p class="First"><a name="INV-5be34084-06bc-4fa4-9004-94a5959c0fbb"></a>When OraVerse was administered as an intraoral submucosal injection 30 minutes after injection of a local anesthetic, 2% lidocaine HCl with 1:100,000 epinephrine, the lidocaine concentration increased immediately after OraVerse intraoral injection. Lidocaine AUC and Cmax values were not affected by administration of OraVerse. OraVerse administration did not affect the PK of epinephrine.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="INV-f1aba8a6-718c-4617-9555-9fc28f1a75e7"></a><a name="section-9"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="INV-c892a7aa-0900-41f4-8054-d62e319a908c"></a><a name="section-9.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><a name="INV-79275b3f-61ee-403e-8fd4-9629d45dca4f"></a>Pregnancy Category C<br>There are no adequate and well-controlled studies in pregnant women. OraVerse should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p><a name="INV-ba84fffb-310a-4c8c-be36-6f324b1d4e58"></a>Oral administration of phentolamine to pregnant rats and mice at doses at least 24 times the recommended dose (based on a 60 kg human) resulted in slightly decreased growth and slight skeletal immaturity of the fetuses. Immaturity was manifested by increased incidence of incomplete or unossified calcaneal and phalangeal nuclei of the hind limb and of incompletely ossified sternebrae. At oral phentolamine doses at least 60 times the recommended dose (based on a 60 kg human), a slightly lower rate of implantation was found in the rat. Phentolamine did not affect embryonic or fetal development in the rabbit at oral doses at least 20 times the recommended dose (based on a 60 kg human). No teratogenic or embryotoxic effects were observed in the rat, mouse, or rabbit studies.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="INV-ede64398-1a69-4ee9-b1c6-5822eb4d6d96"></a><a name="section-9.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First"><a name="INV-93f0fa8b-9433-49d9-b5fc-23fd006a12fa"></a>It is not known whether OraVerse is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when OraVerse is administered to a nursing woman. The unknown risks of limited infant exposure to phentolamine through breast milk following a single maternal dose should be weighed against the known benefits of breastfeeding.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="INV-f30b7487-3927-49d0-abfb-45aa2dd5be9f"></a><a name="section-9.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First"><a name="INV-fd59411f-46cb-4f06-ad9d-36e703da82d8"></a>In clinical studies, pediatric patients between the ages of 3 and 17 years received OraVerse.  The safety and effectiveness of OraVerse have been established in the age group 6-17 years. Effectiveness in pediatric patients below the age of 6 years has not been established. Use of OraVerse in patients between the ages of 6 and 17 years old is supported by evidence from adequate and well-controlled studies of OraVerse in adults, with additional adequate and well-controlled studies of OraVerse in pediatric patients ages 12-17 years old [Studies 1 (mandibular procedures) and 2 (maxillary procedures)] and ages 6-11 years old [Study 3 (mandibular and maxillary procedures)]. The safety, but not the efficacy, of OraVerse has been evaluated in pediatric patients under the age of 6 years old. Dosages in pediatric patients may need to be limited based on body weight. <span class="Italics">[see <a href="#INV-a16c0d08-35ab-46eb-896c-d9280ef6522d">Dosage and Administration (2)]</a></span></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="INV-0c0aed50-d86f-4eab-bdd1-62cdd9f56f89"></a><a name="section-9.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First"><a name="INV-e91c2b76-0017-4e79-a9b8-e45700546d3d"></a>Of the total number of patients in clinical studies of OraVerse, 55 were 65 and over, while 21 were 75 and over. No overall differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="INV-19277e6a-f0c8-4f4b-a32c-d2b6a7292a0e"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First"><a name="INV-9dbb4693-1c87-4638-adc1-130121065d45"></a>No <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> due to acute <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> with phentolamine have been reported.</p>
<p><a name="INV-be5f16c4-c734-42a8-8ecd-31a6604bd29e"></a>Overdosage with parenterally administered phentolamine is characterized chiefly by cardiovascular disturbances, such as <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and possibly <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>.  In addition, the following might occur: excitation, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, pupillary contraction, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
<p><a name="INV-e8349bbc-29b0-4b26-aba9-d442c194abde"></a>There is no specific antidote; treatment consists of appropriate monitoring and supportive care. Substantial decreases in blood pressure or other evidence of <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>-like conditions should be treated vigorously and promptly.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="INV-4c2ee060-7269-412f-a627-e909e35d4b94"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First"><a name="INV-5781d71f-068f-4078-b260-a187a9b6803f"></a>Phentolamine mesylate is phenol,3-[[(4,5-dihydro-1 <span class="Italics">H</span>-imidazol-2-yl)methyl](4-methyl-phenyl)amino]-, methanesulfonate (salt), a non-specific alpha adrenergic blocker.</p>
<p><a name="INV-739cf361-ae61-464c-bba4-6deb8f6679af"></a>Phentolamine mesylate USP is a white to off-white, odorless crystalline powder with a molecular weight of 377.46. It is sparingly soluble in water, soluble in alcohol, and slightly soluble in chloroform. The empirical formulation is C <span class="Sub">17</span>H<span class="Sub">19</span>N<span class="Sub">3</span>O•CH<span class="Sub">4</span>O<span class="Sub">3</span>S, and the chemical structure is:</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=38be9414-87c4-4a8a-9f17-99be0d0a33fa&amp;name=chemical-01.jpg"></div>
<p><a name="INV-cd873e8d-9739-4e75-b3d8-73bf01c7643c"></a>OraVerse (phentolamine mesylate) Injection is a clear, colorless, sterile, non pyrogenic, isotonic, preservative free solution. Each 1.7 mL cartridge contains 0.4 mg phentolamine mesylate, D-mannitol, edetate disodium, and sodium acetate. Either acetic acid or sodium hydroxide is used as necessary to adjust the pH.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="INV-b2d021a6-aae5-46ad-a6b7-11ca2b787d6c"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="INV-cb08963d-e94a-4b40-afb0-fcfc5618a664"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First"><a name="INV-198fa950-d728-42f7-bc5e-acce707436ec"></a>The mechanism by which OraVerse accelerates reversal of soft-tissue anesthesia and the associated functional deficits is not fully understood.  Phentolamine mesylate, the active ingredient in OraVerse, produces an alpha-adrenergic block of relatively short duration resulting in <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span> when applied to vascular smooth muscle.  In an animal model, OraVerse increased local blood flow in submucosal tissue of the dog when given after an intraoral injection of lidocaine 2% with 1:100,000 epinephrine.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="INV-e36bc23f-8ef8-4d30-a597-b876ccd22dee"></a><a name="section-12.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><a name="INV-bb32ac41-8de6-4b91-9ce1-9add4ddf5838"></a>Following OraVerse administration, phentolamine is 100% available from the submucosal injection site and peak concentrations are achieved 10-20 minutes after injection.  Phentolamine systemic exposure increased linearly after 0.8 mg compared to 0.4 mg OraVerse intraoral submucosal injection.  The terminal elimination half-life of phentolamine in the blood was approximately 2-3 hours.</p>
<p><a name="INV-4dc45a08-bcf9-493b-9eaf-4ed28a82c8f2"></a><span class="Bold">Pediatrics</span></p>
<p><a name="INV-ad7835ef-4c09-4e7b-a239-bc49c547b54b"></a>Following OraVerse administration, the phentolamine C<span class="Sub">max</span> was higher (approximately 3.5-fold) in children who weighed between 15 and 30 kg (33 and 66 lbs) than in children who weighed more than 30 kg. However, phentolamine AUC was similar between the two groups. It is recommended that in children weighing 15-30 kg, the maximum dose of OraVerse should be limited to ½ cartridge (0.2 mg) (see Dosage and Administration section).</p>
<p><a name="INV-943f6739-6591-4cdc-91f6-5db34ab6859b"></a>The pharmacokinetics of OraVerse in adults and in children who weighed more than 30 kg (66 lbs) are similar after intraoral submucosal injection.</p>
<p><a name="INV-c0f3e388-7937-4a7a-b71c-27beeee3c17b"></a>OraVerse has not been studied in children under 3 years of age or weighing less than 15 kg (33 lbs). The pharmacokinetics of OraVerse after administration of more than 1 cartridge (0.4mg) has not been studied in children.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="INV-2aeb9b64-f412-44e1-8e2a-c3949d511820"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="INV-2a611caf-c887-4f56-8156-77c807eb08dc"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><a name="INV-32a7209a-e152-41cc-9f3d-0862177f53e2"></a>Carcinogenicity studies with OraVerse have not been conducted.</p>
<p><a name="INV-a5754317-3f39-4291-b30f-14fed1203a03"></a>Phentolamine was not mutagenic in the <span class="Italics">in-vitro</span> bacterial reverse mutation (Ames) assay.  In the <span class="Italics">in-vitro</span> chromosomal aberration study in Chinese hamster ovary cells, numerical aberrations were slightly increased after a 4-hour exposure to phentolamine without metabolic activation and structural aberrations were slightly increased after a 4-hour exposure to phentolamine with metabolic activation only at the highest concentrations tested, but neither numerical nor structural aberrations were increased after a 20-hour exposure without metabolic activation.  Phentolamine was not clastogenic in two <span class="Italics">in-vivo</span> mouse micronucleus assays.  At doses up to 150 mg/kg (143 times human therapeutic exposure levels at the C<span class="Sub">max</span>), phentolamine mesylate was shown to have no adverse effects on male fertility in the rat.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="INV-a0b3da6c-1aaa-49df-9bc9-4573323211c9"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First"><a name="INV-d51eb7ac-8e52-4a77-b6bc-ba7ae398a5fb"></a>The safety and efficacy of OraVerse when used for reversal of soft-tissue anesthesia (STA), i.e., anesthesia of the lips and tongue following a dental procedure that required local anesthesia containing a vasoconstrictor, were evaluated in the following clinical studies. The efficacy of OraVerse on reversal of local anesthesia of the teeth, mandible and maxilla has not been assessed.</p>
<p><a name="INV-9b2171d1-f69c-4658-b5e1-c0963b66617f"></a>Two Phase 3, double-blinded, randomized, multi-center, controlled studies were conducted in dental patients who had mandibular (Study 1) or maxillary (Study 2) restorative or periodontal maintenance procedures and who had received a local anesthetic that contained a vasoconstrictor. The primary endpoint was time to normal lip sensation as measured by patient reported responses to lip palpation. The secondary endpoints included patients’ perception of altered function, sensation and appearance, and their actual functional deficits in smiling, speaking, drinking and <span class="product-label-link" type="condition" conceptid="4266842" conceptname="Dribbling from mouth">drooling</span>, as assessed by both the patient and an observer blinded to the treatment. In the mandibular study, the time to recovery of tongue sensation was also a secondary endpoint.  Patients were stratified by type and amount of anesthetic administered. OraVerse was administered at a cartridge ratio of 1:1 to local anesthetic. The control was a sham injection.</p>
<p><a name="INV-2feddfd7-75d1-48b0-b76e-b4f72a4b7d3a"></a>OraVerse reduced the median time to recovery of normal sensation in the lower lip by 85 minutes (55%) compared to control. The median time to recovery of normal sensation in the upper lip was reduced by 83 minutes (62%). The differences between these times for both studies are depicted in Kaplan-Meier plots for time to normal lip sensation in Figures 1 and 2. Within 1 hour after administration of OraVerse, 41% of patients reported normal lower lip sensation as compared to 7% in the control group, and 59% of patients in the OraVerse group reported normal upper lip sensation as compared to 12% in the control group.</p>
<div class="Figure">
<img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=38be9414-87c4-4a8a-9f17-99be0d0a33fa&amp;name=figure-01.jpg"><p class="MultiMediaCaption">Figure 1:  Kaplan-Meier Plot of Time to Recovery of Normal Sensation in the Lower Lip (ITT Analysis Data Set)</p>
</div>
<div class="Figure">
<img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=38be9414-87c4-4a8a-9f17-99be0d0a33fa&amp;name=figure-02.jpg"><p class="MultiMediaCaption">Figure 2:  Kaplan-Meier Plot of Time to Recovery of Normal Sensation in the Upper Lip (ITT Analysis Data Set)</p>
</div>
<p><a name="INV-f4fb973b-8a48-41d8-96cc-40440281342a"></a>In Study 1 (mandibular), OraVerse accelerated: a) the recovery of the perception of <span class="product-label-link" type="condition" conceptid="4303576" conceptname="Normal appearance">normal appearance</span> and function by 60 minutes (40%), b) the recovery of normal function by 60 (50%) minutes, and c) the recovery of normal sensation in the tongue by 65 minutes (52%).  In Study 2 (maxillary), the recovery of the perception of <span class="product-label-link" type="condition" conceptid="4303576" conceptname="Normal appearance">normal appearance</span> and function was reduced by 60 minutes (50%) and the recovery of normal function was reduced by 45 minutes (43%).</p>
<p><a name="INV-8975be94-eda5-491e-b2d1-eadfbe312038"></a>Study 3, a pediatric, Phase 2, double-blinded, randomized, multi-center, controlled study was conducted in dental patients who had received 2% lidocaine with 1:100,000 epinephrine. Dental patients (n=152, ages 4-11 years) received 1/2 cartridge of local anesthetic if they weighed ≥15 kg but &lt;30 kg, and one-half or one full cartridge if they weighed ≥30 kg at a cartridge ratio of 1:1 to local anesthetic.</p>
<p><a name="INV-59699022-8b52-43b7-8486-c8214fc36920"></a>The median time to normal lip sensation in patients 6 to 11 years of age who were trainable in the lip-palpation procedures, for mandibular and maxillary procedures combined, was reduced by 75 minutes (56%). Within 1 hour after administration of OraVerse, 44 patients (61%) reported normal lip sensation, while only 9 patients (21%) randomized to the control group reported normal lip sensation. In this study, neither the patients’ perception of their appearance or ability to function nor their actual ability to function was evaluated.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="INV-7b907db2-3065-4e6b-9a9e-f07af984a8cf"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><a name="INV-2cba1598-ec5a-400b-bf53-75aefaa1a55e"></a>OraVerse (phentolamine mesylate) Injection 0.4 mg/1.7 mL is supplied in a dental cartridge, in cartons of 10 and 50 cartridges. Each cartridge is individually packaged in a separate compartment of a 10 cartridge <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack.</p>
<p><a name="INV-bd631513-6b8c-4e8d-bf78-91bacbe4ffde"></a>NDC 1500-0101-01</p>
<p><a name="INV-676892e6-fee7-44bf-b2c6-c55c6dc0ea30"></a>NDC 1500-0101-02</p>
<p><a name="INV-9439a16e-6b13-4fe8-9f12-c9ddd96d551f"></a>Store at controlled room temperature, 20-25C (68-77F) with brief excursions permitted between 15-30C (59-86F) (see USP Controlled Room Temperature).</p>
<p><a name="INV-04f5299f-541c-4ed3-8a71-7a0f9ced7646"></a>Protect from direct heat and light. Do not permit to freeze.</p>
<p><a name="INV-394dbfaf-3fdb-49c9-a71a-76a9710e7f92"></a>Manufactured</p>
<p><a name="INV-b702097e-0eea-4cc2-8c83-62362bb74a69"></a>by Novocol Pharmaceutical of Canada, Incorporated<br>Cambridge, Ontario, Canada</p>
<p><a name="INV-b4b570ba-331a-4940-8638-2233d40568b9"></a>for Novalar Pharmaceuticals, Inc.<br>San Diego, CA, 92130</p>
<p><a name="INV-3fcf36f3-ecbb-40e9-a73e-dc63ab7f8cc2"></a>US Patent Nos.: 6,764,678; 6,872,390; 7,229,630</p>
<p><a name="INV-9286ef0f-9d43-4456-b487-44b70f22d75a"></a>Trademark of Novalar Pharmaceuticals, Inc.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="INV-eca06131-20de-43d8-a6a6-f05fae66d20e"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><a name="INV-af7fc906-7328-4634-97e7-58cfa613ad2b"></a>Patients should be instructed not to eat or drink until normal sensation returns.</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ORAVERSE 		
					</strong><br><span class="contentTableReg">phentolamine mesylate injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem"></td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:1500-0101</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBMUCOSAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Phentolamine mesylate</strong> (phentolamine) </td>
<td class="formItem"></td>
<td class="formItem">0.4 mg  in 1.7 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Edetate disodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D-Mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium acetate, trihydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Glacial acetic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:1500-0101-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1.7 mL in 1 CARTRIDGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:1500-0101-02</td>
<td class="formItem">5  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1.7 mL in 1 CARTRIDGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Novalar Pharmaceuticals</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2008<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>73841EBD-97FF-8476-B631-5A6F9A05AAFE</div>
<div>Set id: 38be9414-87c4-4a8a-9f17-99be0d0a33fa</div>
<div>Version: 1</div>
<div>Effective Time: 20080523</div>
</div>
</div> <div class="DistributorName">Novalar Pharmaceuticals</div></p>
</body></html>
